Abstract 100P
Background
Liquid biopsy for circulating tumor DNA is a valuable tool for cancer treatment selection and monitoring but other technologies must be explored to reveal actionable biomarker expression in the blood. We present a novel method to infer biomarker expression from cell-free non-coding small RNAs (smRNAs), including orphan non-coding RNAs (oncRNAs), which are actively secreted and stable in blood. Our platform uses smRNAs as surrogates for tumor transcriptomes and can infer biomarkers in breast cancer patients from 1 ml of plasma.
Methods
We developed a cell-free smRNA assay with an automated, CLIA-certified lab workflow. We screened the smRNA transcriptome to identify smRNAs associated with ESR1 and ERBB2 mRNA expression across breast cancer subtypes in tumor tissue (n=540). We developed a model in tumor and validated our expression scores with published RNA-seq in tumor tissue (TCGA), breast cancer cell lines with conditioned media (RNA-seq from DepMap) (n=10), and plasma from Stage III and IV breast cancer patients (n=75) with immunohistochemistry (IHC) derived hormone receptor (ER and HER2) status.
Results
From 3856 smRNA features, we developed separate smRNA scores for ESR1 and ERBB2 expression. In tumor tissue, we observed strong correlation between smRNA score and mRNA-seq for ESR1 (r=0.81, 95% CI: 0.78-0.84) and ERBB2 (r=0.79, 0.72-0.84), as well as with IHC status (ER, AUC = 0.96, 0.94-0.98; HER2, AUC = 0.87, 0.8-0.94). We confirmed that our scores were calibrated for conditioned media from common breast cancer cell lines with known ER and HER2 status, such that extracellular smRNA scores correlated with mRNA levels (r = 0.83 ERBB2, r = 0.79 ESR1). smRNA scores for baseline patient plasma predicted ER status in HER2- patients (AUC=0.79, 0.62-0.96) and HER2 status in HR- patients (AUC=0.85, 0.45-0.89).
Conclusions
We present the first use of cell-free small RNAs in an automated liquid biopsy assay to accurately infer breast cancer biomarkers from transcriptional profiles. This approach provides a sensitive option to assess potential drug target activity from a single blood draw.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Exai Bio.
Funding
Exai Bio.
Disclosure
L.S. Schwartzberg, E. Boyle, T. Cavazos, M. Karimzadeh, L. Fish, F. Hormozdiari: Financial Interests, Institutional, Full or part-time Employment: Exai Bio. J. Yen: Financial Interests, Institutional, Full or part-time Employment: Exai Bio; Financial Interests, Personal, Stocks/Shares, Former Employee: Guardant Health. H. Heydari: Financial Interests, Institutional, Financially compensated role: Exai Bio. R. Trivedi: Financial Interests, Institutional, Full or part-time Employment: Exai Bio; Financial Interests, Personal, Stocks/Shares, Former Employee: Illumina. A. Lazar: Financial Interests, Institutional, Advisory Role: Exai Bio. B. Alipanahi: Financial Interests, Institutional, Full or part-time Employment: Exai Bio; Financial Interests, Personal, Stocks/Shares: AstraZeneca, Ionis Pharmaceuticals, Moderna Therapeutics, Guardant Health, 23andMe.
Resources from the same session
21P - DNAJC1 inhibit the ferroptosis of glioma cells through stabilizing GPX4 by competing with TRIM21
Presenter: Min Chao
Session: Poster session 07
Resources:
Abstract
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07